Staccato Loxapine in Agitated Patients With Bipolar Disorder
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Efficacy and Safety Study of Staccato® Loxapine for Inhalation in Patients With Bipolar I Disorder and Acute Agitation
Sponsor: Alexza Pharmaceuticals, Inc.
Listed as NCT00721955, this PHASE3 trial focuses on Bipolar I Disorder and remains completed. Sponsored by Alexza Pharmaceuticals, Inc., it has been updated 9 times since 2008, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Feb 2026 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Feb 2017 — Aug 2017 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Jul 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Alexza Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .